Eribulin improved overall Survival in patients with HER-2 negative metastatic breast cancer-comparison to bevacizumab plus paclitaxel-

被引：0
|
作者：
Iwamoto, M. [1 ]
Kawaguchi, K. [1 ]
Terasawa, R. [1 ]
Fujioka, H. [1 ]
Kimura, K. [1 ]
Uchiyama, K. [1 ]
机构：
[1] Osaka Med Coll, Osaka, Japan
来源：
BREAST | 2017年 / 32卷
关键词：
D O I：
10.1016/S0960-9776(17)30224-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P129
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [1] Eribulin improved overall survival in patients with HER-2 negative metastatic breast cancer: Comparison to bevacizumab plus paclitaxel.
    Iwamoto, Mitsuhiko
    Umezaki, Nodoka
    Matsuda, Juuna
    Kawaguchi, Kanako
    Terasawa, Risa
    Sato, Nayuko
    Fujioka, Hiroya
    Kimura, Kosei
    Tanaka, Satoru
    Uchiyama, Kazuhisa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Eribulin vs. Eribulin plus Bevacizumab in advanced-line treatment of Her-2 negative metastatic breast cancer
    Rossi, G.
    Martellucci, I.
    Marsili, S.
    Petrioli, R.
    Nardone, V.
    Chirra, M.
    Torre, P.
    Messutti, L.
    Multari, A. G.
    Francini, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
    Dedes, Konstantin J.
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Pestalozzi, Bernhard C.
    Fink, Daniel
    Brauchli, Peter
    Szucs, Thomas D.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (08) : 1397 - 1406
  • [4] Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation
    Dedes, K. J.
    Matter-Walstra, K.
    Schwenkglenks, M.
    Pestalozzi, B. C.
    Fink, D.
    Szucs, T. T.
    CANCER RESEARCH, 2009, 69 (02) : 378S - 378S
  • [5] A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer
    Tsushita, N.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Kitano, A.
    Nishikawa, T.
    Shimomura, A.
    Noguchi, E.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer
    Miano, S. T.
    Rossi, G.
    Marsili, S.
    Petrioli, R.
    Pascucci, A.
    Francini, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 22 - 23
  • [7] Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer
    Berghoff, Anna S.
    Bago-Horvath, Zsuzsanna
    Dubsky, Peter
    Rudas, Margaretha
    Pluschnig, Ursula
    Wiltschke, Christoph
    Gnant, Michael
    Steger, Guenther G.
    Zielinski, Christoph C.
    Bartsch, Rupert
    BREAST JOURNAL, 2013, 19 (02): : 149 - 155
  • [8] THE BENEFIT OF HER-2 TARGETED THERAPIES ON OVERALL SURVIVAL OF PATIENTS WITH METASTATIC BREAST CANCER - A SYSTEMATIC REVIEW
    Alves, C.
    Mendes, D.
    Andrade, S.
    Marques, Batel F.
    VALUE IN HEALTH, 2014, 17 (07) : A620 - A620
  • [9] Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer
    Wu, Qiuji
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Wang, Feng
    Li, Qiu
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) : 153 - 159
  • [10] Trastuzumab plus paclitaxel in HER-2 positive metastatic breast cancer: A single institutional experience
    Capobianco, A. M. L.
    Di Leo, P.
    Bochicchio, A. M.
    Coccaro, M.
    Romano, G.
    Tartarone, A.
    Ardito, R.
    Musto, C.
    Barone, M.
    Guarigli, R.
    Di Renzo, N.
    ANNALS OF ONCOLOGY, 2005, 16 : 141 - 142
12345